A blue check for Sputnik V—and a cautionary marketing tale for the pharma industry? The Russian-developed coronavirus vaccine nabbed verified status from Twitter last week, doubling down on its broadcasting wave of tweets, retweets and plenty of American-style attitude.

But is the now-authenticated social media account a pharma influencer case study or a cautionary tale of disinformation?

While the account’s relaxed tone may offer some lightening-up lessons for pharma, the Sputnik V public relations push is also implicated in a newly revealed Russian disinformation campaign to propel vaccine sales.